litlas
Log inCreate account

Mark J. Millan

Active 1981–2024

123
Papers
26,742
Citations
92
h-index
123
i10-index

Citations

Citations per year for Mark J. Millan1962: 1 citations1980: 1 citations1982: 2 citations1983: 3 citations1985: 4 citations1986: 9 citations1987: 12 citations1988: 14 citations1989: 16 citations1990: 16 citations1991: 22 citations1992: 24 citations1993: 17 citations1994: 11 citations1995: 23 citations1996: 16 citations1997: 40 citations1998: 67 citations1999: 73 citations2000: 153 citations2001: 120 citations2002: 142 citations2003: 184 citations2004: 209 citations2005: 207 citations2006: 242 citations2007: 209 citations2008: 277 citations2009: 215 citations2010: 266 citations2011: 244 citations2012: 223 citations2013: 235 citations2014: 214 citations2015: 238 citations2016: 236 citations2017: 165 citations2018: 149 citations2019: 634 citations2020: 725 citations2021: 687 citations2022: 539 citations2023: 387 citations2024: 509 citations2025: 268 citations2026: 14 citations1963–1979: no citations, so these years are not shown1981: no citations, so this year is not shown1984: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,451 citing papers, 23.4% of this breakdownUnited Kingdom: 826 citing papers, 7.9% of this breakdownChina: 794 citing papers, 7.6% of this breakdownGermany: 597 citing papers, 5.7% of this breakdownFrance: 593 citing papers, 5.7% of this breakdownItaly: 571 citing papers, 5.4% of this breakdownCanada: 479 citing papers, 4.6% of this breakdownSpain: 362 citing papers, 3.4% of this breakdownAustralia: 275 citing papers, 2.6% of this breakdownNetherlands: 252 citing papers, 2.4% of this breakdownJapan: 249 citing papers, 2.4% of this breakdownSwitzerland: 244 citing papers, 2.3% of this breakdown
0%23.4%Other 26.6%

Institutions

Fields

  • Medicine40.2%
  • Neuroscience33.2%
  • Biochemistry, Genetics and Molecular Biology15.2%
  • Psychology6.1%
  • Pharmacology, Toxicology and Pharmaceutics1.2%
  • Computer Science1%
  • Other3.1%

Topics

  • Neurotransmitter Receptor Influence on Behavior6.6%
  • Neuroscience and Neuropharmacology Research5.5%
  • Pain Mechanisms and Treatments5.1%
  • Receptor Mechanisms and Signaling4.3%
  • Tryptophan and brain disorders3.3%
  • Schizophrenia research and treatment2.9%
  • Other72.3%

Coauthors

All papers

Open in search
  1. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing

    Authors: Stephen C. Cunnane, Eugenia Trushina, Cecilie Morland, Alessandro Prigione, Gemma Casadesús, Zane B. Andrews, M. Flint Beal, Linda H. Bergersen, Roberta Dı́az Brinton, Suzanne de la Monte, Anne Eckert, Jenni Harvey, Ross Jeggo, Jack H. Jhamandas, Oliver Kann, Clothide Mannoury la Cour, William Martin, Gilles Mithieux, Paula I. Moreira, Michael P. Murphy, Klaus‐Armin Nave, Tal Nuriel, Stéphane H. R. Oliet, Frédéric Saudou, Mark P. Mattson, Russell H. Swerdlow, Mark J. Millan - Nature Reviews Drug Discovery 2020 cited by 990

  2. Descending control of pain

    Authors: Mark J. Millan - Progress in Neurobiology 2002 cited by 3,004

  3. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing

    Authors: Barry Boland, Wai Haung Yu, Olga Corti, Bertrand Mollereau, Alexandre Henriques, Erwan Bézard, Greg Pastores, David C. Rubinsztein, Ralph A. Nixon, Michael R. Duchen, Giovanna R. Mallucci, Guido Kroemer, Beth Levine, Eeva‐Liisa Eskelinen, Fanny Mochel, Michael Spedding, Caroline Louis, Olivier R. Martin, Mark J. Millan - Nature Reviews Drug Discovery 2018 cited by 549

  4. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

    Authors: Mark J. Millan, Yves Agid, Martin Brüne, Edward T. Bullmore, Cameron S. Carter, Nicola S. Clayton, Richard C. Connor, Sabrina Davis, J.F.W. Deakin, Robert J. DeRubeis, Bruno Dubois, Mark A. Geyer, Guy M. Goodwin, Philip Gorwood, Thérèse M. Jay, Marian Joëls, Isabelle M. Mansuy, Andreas Meyer‐Lindenberg, Declan Murphy, Edmund T. Rolls, B. Saletu, Michael Spedding, John A. Sweeney, Miles A. Whittington, Larry J. Young - Nature Reviews Drug Discovery 2012 cited by 1,297

  5. Prevention of Psychosis

    Authors: Paolo Fusar‐Poli, Gonzalo Salazar de Pablo, Christoph U. Correll, Andreas Meyer‐Lindenberg, Mark J. Millan, Stefan Borgwardt, Silvana Galderisi, Andreas Bechdolf, Andrea Pfennig, Lars Vedel Kessing, Thérèse van Amelsvoort, Dorien H. Nieman, Katharina Domschke, Marie‐Odile Krebs, Nikolaos Koutsouleris, Philip McGuire, Kim Q., Celso Arango - JAMA Psychiatry 2020 cited by 466

  6. Altering the course of schizophrenia: progress and perspectives

    Authors: Mark J. Millan, Annie Andrieux, George Bartzokis, Kristin S. Cadenhead, Paola Dazzan, Paolo Fusar‐Poli, Jürgen Gallinat, Jay N. Giedd, Dennis R. Grayson, Markus Heinrichs, René S. Kahn, Marie‐Odile Krebs, Marion Leboyer, David A. Lewis, Òscar Marín, Philippe Marin, Andreas Meyer‐Lindenberg, Patrick D. McGorry, Philip McGuire, Michael J. Owen, Paul H. Patterson, Akira Sawa, Michael Spedding, Peter J. Uhlhaas, Flora M. Vaccarino, Claes Wahlestedt, Daniel M. Weinberger - Nature Reviews Drug Discovery 2016 cited by 513

  7. AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1

    Authors: Alejandro Díaz‐Holguín, Marcus Saarinen, Duc Duy Vo, Andrea Sturchio, Niclas Branzell, Israel Cabeza de Vaca, Huabin Hu, Núria Mitjavila-Domènech, Annika Lindqvist, Paweł Baranczewski, Mark J. Millan, Yunting Yang, Jens Carlsson, Per Svenningsson - Science Advances 2024 cited by 51

  8. Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment

    Authors: Mark J. Millan, K.C.F. Fone, Thomas Steckler, William P. Horan - European Neuropsychopharmacology 2014 cited by 345

  9. Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling

    Authors: Laura Cavalleri, Emilio Merlo Pich, Mark J. Millan, Cristiano Chiamulera, Tilo Kunath, PierFranco Spano, Ginetta Collo - Molecular Psychiatry 2017 cited by 155

  10. Deconstructing Vulnerability for Psychosis: Meta-Analysis of Environmental Risk Factors for Psychosis in Subjects at Ultra High-Risk

    Authors: Paolo Fusar‐Poli, Michela Tantardini, Stefania De Simone, Valentina Ramella‐Cravaro, Dominic Oliver, Jack Kingdon, Magdalena Kotlicka‐Antczak, Lucia Valmaggia, J. Lee, Mark J. Millan, Silvana Galderisi, Umberto Balottin, Valdo Ricca, Philip McGuire - European Psychiatry 2016 cited by 305

  11. The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

    Authors: Mark J. Millan, Alain P. Gobert, F. Lejeune, A Dekeyne, Adrian Newman‐Tancredi, Valérie Pasteau, Jean‐Michel Rivet, Didier Cussac - Journal of Pharmacology and Experimental Therapeutics 2003 cited by 512

  12. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

    Authors: Christian de Bodinat, Béatrice Guardiola‐Lemaître, Elisabeth Mocaër, Pierre Renard, Carmen Muñoz, Mark J. Millan - Nature Reviews Drug Discovery 2010 cited by 588

  13. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions

    Authors: Mark J. Millan, Philippe Marin, J BOCKAERT, Clotilde Mannoury-la-cour - Trends in Pharmacological Sciences 2008 cited by 314

  14. Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review

    Authors: Mark J. Millan - Progress in Neurobiology 2017 cited by 144

  15. Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry

    Authors: Philippe De Deurwaerdère, Giuseppe Di Giovanni, Mark J. Millan - Progress in Neurobiology 2016 cited by 124

  16. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action

    Authors: Mark J. Millan - Therapeutic Advances in Psychopharmacology 2022 cited by 42

  17. TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-363856

    Authors: Marcus Saarinen, Ioannis Mantas, Ivana Flais, Richard Ågren, Kristoffer Sahlholm, Mark J. Millan, Per Svenningsson - Neuropsychopharmacology 2022 cited by 33

  18. The induction of pain: an integrative review

    Authors: Mark J. Millan - Progress in Neurobiology 1999 cited by 1,763

  19. 5‐HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia

    Authors: Julie Meffre, Séverine Chaumont‐Dubel, Clotilde Mannoury la Cour, Florence Loiseau, David J. Watson, Anne Dekeyne, Martial Sevéno, Jean‐Michel Rivet, Florence Gaven, Paul Déléris, Denis Hervé, K.C.F. Fone, Joël Bockaert, Mark J. Millan, Philippe Marin - EMBO Molecular Medicine 2012 cited by 165

  20. Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth

    Authors: Fanny Duhr, Paul Déléris, Fabrice Raynaud, Martial Sevéno, Séverine Morisset‐Lopez, Clotilde Mannoury la Cour, Mark J. Millan, Joël Bockaert, Philippe Marin, Séverine Chaumont‐Dubel - Nature Chemical Biology 2014 cited by 116

  21. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

    Authors: Mark J. Millan - Pharmacology & Therapeutics 2006 cited by 544

  22. Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

    Authors: Mark J. Millan, Lisa Maiofiss, Didier Cussac, Valérie Audinot, Jean A. Boutin, Adrian Newman‐Tancredi - Journal of Pharmacology and Experimental Therapeutics 2002 cited by 483

  23. P62 accumulates through neuroanatomical circuits in response to tauopathy propagation

    Authors: François-Xavier Blaudin de Thé, Benjamin Lassus, Ari W. Schaler, Stephanie L. Fowler, Chris N. Goulbourne, Ross Jeggo, Clotilde Mannoury la Cour, Mark J. Millan, Karen Duff - Acta Neuropathologica Communications 2021 cited by 24

  24. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain

    Authors: Anne Amphoux, Vincent Vialou, Eva Drescher, Michael Brüss, Clotilde Mannoury la Cour, Catherine Rochat, Mark J. Millan, Bruno Giros, Heinz Bönisch, Sophie Gautron - Neuropharmacology 2006 cited by 212